SPI-1620

DRUG3 trials

Sponsors

Spectrum Pharmaceuticals, Inc

Conditions

Biliary CancerCarcinomaNon Small Cell Lung Cancer (NSCLC)

Phase 1

A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma

CompletedNCT00613691

Spectrum Pharmaceuticals, IncCarcinoma

Start: 2008-01-31End: 2012-12-31Updated: 2013-10-21

Phase 2

Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)

TerminatedNCT01741155

Spectrum Pharmaceuticals, IncNon Small Cell Lung Cancer (NSCLC)

Start: 2013-05-31End: 2015-07-31Updated: 2021-10-13

Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer

TerminatedNCT01773785

Spectrum Pharmaceuticals, IncBiliary Cancer

Start: 2013-04-30End: 2015-09-30Updated: 2021-10-13

Related Papers

Repeated administration of ET(B) receptor agonist, IRL-1620, produces tachyphylaxis only to its hypotensive effect.

2009-08-0814 citations